All In Biotech

Drug Trial Radar · NCT04810611

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome

Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

33

Actual

Start

Jun 18, 2021

Primary completion

Apr 19, 2024

Study completion Apr 19, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • MBG453Drug

    Anti-TIM3 monoclonal antibody

  • NIS793Drug

    Anti-TGF-β monoclonal antibody

  • canakinumabDrug

    Anti-IL-1β monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose interruption reductionTime frame: 30 Months
  2. Incidence of DLTsTime frame: 30 Months
  3. Dose intensityTime frame: 30 Months
  4. AE and SAE incidenceTime frame: 30 months

Locations

13 sites in 7 countries. Site status is shown where the registry gives one.

  • City Of Hope National Med Center Oncology

    Duarte, California

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Massachusetts General Hospital .

    Boston, Massachusetts

  • The Ohio State University Wexner Medical Center .

    Columbus, Ohio

  • MD Anderson Cancer Center/University of Texas MD Anderson

    Houston, Texas

  • Novartis Investigative Site

    Prahran, Victoria, Australia

  • Novartis Investigative Site

    Tel Aviv, Israel

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Salamanca, Castille and León, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.